FBXL20

FBXL20 is the substrate-recognition F-box subunit of an SCF (Skp1-Cullin1-F-box) E3 ubiquitin ligase that controls the abundance of diverse regulatory proteins by targeting them for polyubiquitination and proteasomal degradation, thereby linking the p53 pathway to autophagy, apoptosis, phosphatase signaling, and synaptic vesicle dynamics (PMID:25593308, PMID:34731788). In the DNA-damage response, p53 transcriptionally induces FBXL20, which then recognizes CDK-phosphorylated Vps34 (the class III PI3K catalytic subunit) and drives its degradation to suppress autophagy and receptor endocytosis (PMID:25593308). The same p53/FBXL20 axis destabilizes the PP2A regulatory subunit PR55α, restraining downstream c-Myc oncogenic signaling (PMID:34731788). FBXL20 also governs the apoptotic threshold by degrading the pro-apoptotic proteins PUMA and BAX, an activity stimulated by AKT1-mediated phosphorylation; loss of AKT1 activates GSK3α/β, which in turn promotes FBXL20's own degradation through the F-box protein FBXO31 (PMID:34587475). Additional substrates include the immune receptor 4-1BB/TNFRSF9, where FBXL20 ubiquitinates the mature N-glycosylated form at its intracellular domain (PMID:35112462), and the synaptic vesicle proteins VGLUT1 and VAMP1, whose FBXL20-driven turnover modulates glutamatergic neurotransmission in hippocampal neurons under chronic stress (PMID:38211741).

1. 2015 High

   Established FBXL20 as a p53-inducible SCF substrate receptor that couples DNA damage to autophagy and endocytosis by destroying phospho-Vps34, defining its founding mechanistic role.

   Evidence Co-IP, ubiquitination assays, proteasome inhibitor rescue, siRNA, p53 reporter assays, and autophagy/endocytosis readouts in mammalian cells

   PMID:25593308

   Open questions at the time

   • Degron features beyond CDK-phosphorylated Vps34 not generalized
   • No structural model of the SCF-FBXL20-substrate complex
2. 2021 High

   Showed FBXL20 sets the apoptotic threshold by degrading PUMA and BAX under AKT1 control, and is itself regulated by a GSK3/FBXO31 degradation loop, revealing reciprocal kinase governance of FBXL20 activity and stability.

   Evidence Co-IP, ubiquitination assays, RNAi, kinase activity assays, apoptosis flow cytometry, and tumor growth assays

   PMID:34587475

   Open questions at the time

   • FBXL20 phosphosite(s) targeted by AKT1 not mapped
   • Mechanism by which GSK3 primes FBXL20 for FBXO31 recognition unresolved
3. 2021 High

   Extended the p53/FBXL20 axis to phosphatase signaling by identifying PR55α as a substrate, linking FBXL20 to PP2A regulation and c-Myc-driven transformation.

   Evidence siRNA, ubiquitination assays, protein stability Westerns, HPV-E6 p53 degradation and p53R175H mutant, anchorage-independent growth in cells

   PMID:34731788

   Open questions at the time

   • Degron on PR55α not defined
   • Direct contribution to PP2A complex remodeling not quantified
4. 2022 Medium

   Identified the immune receptor 4-1BB as an FBXL20 substrate, indicating a role in receptor homeostasis through degradation of the mature glycosylated form.

   Evidence BioID screen, Co-IP, ubiquitination assays, proteasome inhibitor rescue, domain mapping

   PMID:35112462

   Open questions at the time

   • Physiological context of 4-1BB regulation by FBXL20 in immune cells not tested
   • Single lab, two orthogonal methods
5. 2024 Medium

   Connected FBXL20 to synaptic function by showing it degrades VGLUT1 and VAMP1 in hippocampal neurons, with knockdown rescuing chronic-stress synaptic deficits and depression-like behavior.

   Evidence Proteomics, in vivo shRNA via stereotaxic viral injection, TEM, ubiquitination assays, glutamate probe imaging, and Co-IP

   PMID:38211741

   Open questions at the time

   • Direct degron recognition on VGLUT1/VAMP1 not mapped
   • Upstream signal driving FBXL20 elevation under stress unknown
6. 2016 Low

   Implicated FBXL20 in synaptic vesicle release through RIM1 turnover, with overexpression reducing seizure activity, suggesting a neuronal substrate beyond the later vesicle proteins.

   Evidence Immunofluorescence, IHC, Western blot, lentiviral overexpression in rats, and seizure monitoring in a pilocarpine epilepsy model

   PMID:27502938

   Open questions at the time

   • No direct ubiquitination assay for RIM1 reported
   • Causal degradation versus indirect effect not distinguished
   • Single lab

• How FBXL20 selects among its many substrates across pathways and tissues, and what shared or distinct degrons it recognizes, remains unresolved.
• No unifying degron consensus established across substrates
• Tissue-specific substrate prioritization unknown
• No structural basis for substrate recognition